Pacific Biosciences of California PACB
$1.63 −$0.13 (-7.39%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $1.63 +0.28%
Open$1.69
Prev close$1.76
Day range$1.61 – $1.73
Volume13.69M
Market cap$510.07M
P/E (TTM)–
Dividend yield–
PACB Stock News
Headlines matching Pacific Biosciences of California or the PACB ticker, most recent first.
- CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating
- Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
- TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
- Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX)
- CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
- Analysts Are Bullish on Top Healthcare Stocks: Pacific Biosciences (PACB), 20/20 Biolabs, Inc. (AIDX) Positive
- Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Cuts Target Price to $1 Negative
- Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $2 Positive
- UBS Initiates Pacific Biosciences of California(PACB.US) With Hold Rating, Announces Target Price $2.7
- CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Announces Target Price $3
- Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $3 Positive
- Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Raises Target Price to $2 Positive
- Earnings Flash (PACB) Pacific Biosciences of California, Inc. Posts Q3 Adjusted Loss $0.11 per Share, Vs. FactSet Est of $-0.13 Negative
- Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Maintains Target Price $1.25
- Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $2.5 Positive
No comments yet — be the first to weigh in on PACB.
Sign in to join the discussion.